Menkes disease and response to copper histidine: An Indian case series

Overcoming barriers in Menkes disease: A standardized high quality and stable injectable copper histidinate

Copper histidinate injection, utilized for Menkes disease treatment, suffers from chemical instability and the absence of validated quality control methods. This study aims to develop an optimized stability formulation of copper histidinate and to evaluate its chemical stability using validated methods, supported by microbiological and elemental impurity risk assessment. The original formulation was modified by altering the stoichiometric ratio of histidine to copper from 1:2 to 1:3 (Cu-Hiinj 1:3). The results indicated a significantly enhanced stability for Cu-Hiinj 1:3, maintaining copper integrity under all tested conditions, unlike Cu-Hiinj 1:2, which exhibited notable copper degradation at temperatures above 8°C. The new formulation displayed no degradation except at 60°C, rendering the calculation of validity period (t90) unfeasible. This significantly enhanced stability is attributed to the increased histidine content in Cu-Hiinj 1:3, which augments the chelating capacity of the copper-histidine complex. Additionally, two validated analytical methods, namely flame atomic absorption spectrometry and redox titration (the latter being an accessible analytical method for compounding pharmacies), demonstrated precision and accuracy for copper quantification, with negligible matrix effects. Sterility tests confirmed the absence of microbial growth, validating the aseptic manufacturing process. This study extends and optimizes the manufacturing procedure by incorporating active principles as salts or neutral substances and accommodating a broader pH range. The Cu-Hiinj 1:3 formulation not only offers enhanced stability but also shows potential for industrial production, thus improving access to Menkes disease treatment while ensuring safety and efficacy.

The interplay between copper metabolism and microbes: in perspective of host copper-dependent ATPases ATP7A/B

Copper, a vital element in various physiological processes, is transported from the gastrointestinal tract to tissues and cells through diverse copper transporters. Among these transporters, ATP7A and ATP7B play significant roles in regulating systemic copper metabolism and exhibit precise regulation in their intracellular trafficking. These transporters undergo dynamic shuttling between the trans-Golgi network (TGN) and the plasma membrane via the endocytic recycling mechanism, which involves the retromer and other associated factors. Interestingly, the antimicrobial attribute of copper implies a potential connection between microbial infection and copper metabolism. Several microbes, including Salmonella enterica, Cryptococcus, Influenza A virus (IAV) and Zika virus (ZIKV) have been observed to impact the regulatory mechanisms of ATP7A/B, either directly or indirectly, as a means of survival. This review summarizes the key features and trafficking mechanisms of the copper transporters ATP7A/B, and examines the intricate interplay between microbes and copper metabolism. Ultimately, it highlights how microbes can perturb copper homeostasis through interactions with host factors, offering valuable insights into the mechanistic aspects of host-microbe interactions.

Health-Related Quality of Life and Family Functioning of Primary Caregivers of Children with Menkes Disease

BACKGROUND

Menkes disease (MD; OMIM #309400) is a progressive neurodegeneration that results from abnormalities in the copper metabolism which are already present before birth. It is an extremely rare condition. The study was conducted to assess the quality of life of children with MD syndrome and the impact of the disease on family functioning.

METHODS

A cross-sectional questionnaire survey was used. The subjects were 16 parents of children with MD. The method used was the Paediatric Quality of Life Inventory and the PedsQL Family Impact Module and the author's own questionnaire.

RESULTS

Quality of life (QOL) was 29.14 (SD = 14.73), with the lowest for physical functioning (M = 10.55; SD = 10.26) and highest for emotional functioning (M = 48.13; SD = 29.43). The highest score was on the family relationships domain (M = 56.25, SD = 20.38) and the cognitive functioning domain (M = 50.00, SD = 19.24) and the lowest was on the daily activities' domain (M = 32.29, SD = 20.38) and the physical functioning domain (M = 39.84, SD = 14.90). The analysis did not show statistically significant relationships between age (p = 0.193) and the number of epileptic seizures a week (p = 0.641) and the overall QOL of the children studied. No statistically significant relationships were found between treatment with copper histidine and the overall QOL of the children (p = 0.914) and in physical functioning (p = 0.927), emotional functioning (p = 0.706), and social functioning (p = 0.751). The presence of comorbidities did not have an influence on the overall QOL.

CONCLUSIONS

MD has a moderate impact on the functioning of the families of the affected children. The age of the child, number of epileptic seizures a week, feeding method (oral feeding or feeding via a PEG tube), and treatment with copper histidine do not have a significant impact on the QOL of children with MD.

Histidine: A Systematic Review on Metabolism and Physiological Effects in Human and Different Animal Species

Histidine is an essential amino acid (EAA) in mammals, fish, and poultry. We aim to give an overview of the metabolism and physiological effects of histidine in humans and different animal species through a systematic review following the guidelines of PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). In humans, dietary histidine may be associated with factors that improve metabolic syndrome and has an effect on ion absorption. In rats, histidine supplementation increases food intake. It also provides neuroprotection at an early stage and could protect against epileptic seizures. In chickens, histidine is particularly important as a limiting factor for carnosine synthesis, which has strong anti-oxidant effects. In fish, dietary histidine may be one of the most important factors in preventing cataracts. In ruminants, histidine is a limiting factor for milk protein synthesis and could be the first limiting AA for growth. In excess, histidine supplementation can be responsible for eating and memory disorders in humans and can induce growth retardation and metabolic dysfunction in most species. To conclude, the requirements for histidine, like for other EAA, have been derived from growth and AA composition in tissues and also have specific metabolic roles depending on species and dietary levels.

A systematic review and evidence-based guideline for diagnosis and treatment of Menkes disease

Menkes disease is a rare X-linked neurodegenerative disorder caused by defect in copper metabolism. Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. We aim at proposing a guideline for prenatal and neonatal diagnosis and for disease-modifying treatment of Menkes disease, guided by a systematic review of the literature, and built in conjunction with medical experts, methodologists and patient representatives. Thirteen articles were used for our recommendations that were based on GRADE system. Reviewed evidence suggests that prenatal genetic diagnosis in families with previous diagnosis of Menkes disease is feasible; analysis of plasma catecholamine levels is accurate for neonatal diagnosis of Menkes disease; treatment with copper-histidine is effective to increase survival and reduce neurologic burden of the disease if initiated in the neonatal period; and, treatment indication should not be guided by patient's genotype. In conclusion, our guideline can contribute to standardize some aspects of the clinical care of patients with Menkes disease, especially reducing disease burden and mortality and providers' and families' anxiety.

Spontaneous retroperitoneal hemorrhage in Menkes disease: A rare case report

RATIONALE

Menkes disease (MD), also known as Menkes kinky hair disease, is a fatal neurodegenerative disease caused by a defect in copper metabolism. The symptoms involve multiple organ systems, such as the brain, lung, gastrointestinal tract, urinary tract, connective tissue, and skin. There is currently no cure for this disease entity, and patients with the classic form of MD usually die from complications between 6 months and 3 years of age. Intracranial hemorrhage secondary to tortuous intracranial arteries is a well-known complication of MD, but spontaneous retroperitoneal hemorrhage, to the best of our knowledge, has never been reported in a patient with MD. Herein, we describe the first case of retroperitoneal hematoma as a complication of MD in a 4-year-old boy.

PATIENT CONCERNS

A 4-year-old Taiwanese male patient with MD was referred to the hospital and presented with a palpable epigastric mass.

DIAGNOSES

On the basis of the findings of ultrasonography and enhanced computed tomography, the diagnosis was retroperitoneal hematoma.

INTERVENTIONS

Interventions included laparotomy with evacuation of the hematoma, manual compression, and suture of the bleeding vessels.

OUTCOMES

There were no postoperative complications.

LESSONS

This case emphasizes that bleeding in patients with MD is possible at any site in the body owing to the unstable structure of the connective tissues. Timely diagnosis with proper imaging studies can lead to prompt and appropriate management and save patients from this life-threatening condition.